ALNYALNYLAM PHARMACEUTICALS, INC.
Health Care
Net Income (Loss) Attributable to Parent revised up 68.2% for Q3 2025
This is the 6th largest revision in ALNY's history.
Net Income (Loss) Attributable to Parent·Q3 2025
Major restatement-$18.3M▲ 68.2%
was-$57.5M
Revised up in a 10-Q.
Verify against SEC filingsShow
As reported-$57.5M
Accepted 2025-05-010001178670-25-000052
Restated-$18.3M
Accepted 2026-10-290001178670-26-000076
NetIncome · reported 6 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time ALNY — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.